Last reviewed · How we verify
AB023- Dose 1
AB023 is a small molecule that targets the PI3K delta subunit.
AB023 is a small molecule that targets the PI3K delta subunit. Used for Relapsed or refractory chronic lymphocytic leukemia, Relapsed or refractory follicular lymphoma.
At a glance
| Generic name | AB023- Dose 1 |
|---|---|
| Also known as | xisomab 3G3- Dose 1, xisomab 3G3- Dose 2 |
| Sponsor | Aronora, Inc. |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting PI3K delta, AB023 modulates the immune response and has shown promise in treating various hematological malignancies.
Approved indications
- Relapsed or refractory chronic lymphocytic leukemia
- Relapsed or refractory follicular lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis (PHASE2)
- Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |